Navigation Links
Roche to Acquire Ventana for $89.50 per share
Date:1/22/2008

Roche and Ventana Reach Definitive Merger Agreement

BASEL, Switzerland and TUCSON, Ariz., Jan. 22 /PRNewswire-FirstCall/ -- Roche (SWX: ROG.VX; RO.S; OTCQX: RHHBY), a world-leading healthcare provider of pharmaceuticals and diagnostics, and Ventana Medical Systems ("Ventana") (Nasdaq: VMSI) today announced that they have signed a definitive merger agreement. Under the terms of the agreement, Roche will increase the purchase price in the tender offer for Ventana common shares to $89.50 per share in cash (or an aggregate of approximately $3.4 billion on a fully diluted basis), and Ventana's Board of Directors will recommend that Ventana's shareholders tender their shares to Roche. The merger agreement has been approved by the boards of Ventana and Roche. This offer represents a premium of 4.9% to Ventana's closing price on January 18, 2008, a 19.3% premium to Roche's initial offer on June 27, 2007, and a 72.3% premium to Ventana's closing price on June 22, 2007 (the last trading day prior to the announcement of Roche's initial offer). The acquisition of Ventana, a leader in the fast-growing histopathology (tissue-based diagnostics) segment, will allow Roche to broaden its diagnostic offerings and complement its world leadership in both in-vitro diagnostic systems and oncology therapies.

Under the terms of the merger agreement, Roche will amend its existing tender offer to acquire all of the outstanding common shares of Ventana to reflect the terms of the merger agreement. The amended offer will increase the offer price to $89.50 per share in cash, expire at 7:00 p.m., New York City time on Thursday, February 7, 2008 and be subject to, among other things, the conditions that there are validly tendered and not withdrawn,
'/>"/>

SOURCE Roche; Ventana Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Roche Extends Tender Offer for Ventana
2. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
3. Roche Files IND for Second Genmab Antibody
4. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
5. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
6. MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York
7. Roche Diagnostics Launches CoaguChek XS Plus System to Provide New PT/INR Point-of-Care Solution for Non-Waived Anticoagulation Services
8. Kosan to Reacquire Epothilone Program From Roche
9. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
10. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
11. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Sinovac Biotech Ltd. (Nasdaq: SVA), a leading ... unaudited financial results for the fourth quarter and full ... 2014 Financial Highlights(Compared to the fourth quarter 2013) ... of 11.4% from $22.9 million in the prior year ... pandemic influenza vaccine of $0.1 million in the fourth ...
(Date:4/20/2015)... 2015 Whitehouse Laboratories is pleased and ... most recent Food and Drug Administration (FDA) inspection and ... five day, GMP compliance inspection, as based upon 21CFR ... through April 6th and was granted NAI (no action ... the strict Good Manufacturing Practice (GMP) quality system required ...
(Date:4/17/2015)... Reed Technology and Information Services ... management, preparation, and submission to the U.S. Food and ... new Lot Distribution Report (LDR) service for manufacturers of ... with the FDA’s new rule on electronic submission of ... the volume and timing of particular biologics introduced to ...
(Date:4/17/2015)... April 17, 2015  Guggenheim Securities, the investment banking ... the hiring of William Tanner as a ... Mr. Tanner will start work at Guggenheim in May ... office. "Bill brings a wealth of ... our experienced and highly acclaimed healthcare team," said ...
Breaking Biology Technology:Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2
... , NEW ... a new market research report is available ... Trial Locations - Eastern Europe: Market dynamics ... , http://www.reportlinker.com/p0165658/Emerging-Clinical-Trial-Locations---Eastern-Europe-Market-dynamics-and-the-changing-healthcare-and-regulatory-environment.html , Over ...
... , Former Majority Leader Richard ... Communities for "Best and Brightest Forum on Medical Innovation" ... of New Jersey,s most prominent leaders in biopharmaceuticals, research, medicine ... discuss the importance of medical innovation in New Jersey, and ...
... , SPRINGFIELD, Ill., Dec. 1 Prairie ... it was recently awarded two statuettes at the first-ever CLIO ... The CLIO Healthcare Awards recognizes creative excellence and innovation in ... CLIO Awards, one of the world,s most recognized awards competitions ...
Cached Biology Technology:Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 2New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 3New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 4New Jersey's Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development 5Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... for Q1 2015 attributed to somewhat higher than 125 ... in the year-end report 2014 that revenues for Q1 ... that the company reported for Q4 2014. The operating ... to be negative. The complete interim report will as ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... PHILADELPHIA , Feb. 20, 2013   LaserLock ... in providing state-of-the-art authentication solutions to governments, pharmaceuticals, ... a provisional patent application for a Characteristic ... simultaneously identify counterfeit products and protect against identity ...
... in the Journal of the Academy of Nutrition and ... a connection between diet and acne, particularly from high glycemic ... (MNT) can play an important role in acne treatment. ... their adolescent and young adult years. Acne influences quality of ...
... brain, patterned on engineering control theory, may some day ... and migraines, according to a Penn State researcher who ... more complex brain models emerge. "The dual ... of the most important developments in mathematics of the ...
Cached Biology News:LaserLock Technologies Files for Provisional Patent Enabling Mobile Phones with Anti-Counterfeiting Technology 2Increasing evidence links high glycemic index foods and dairy products to acne 2Engineering control theory helps create dynamic brain models 2Engineering control theory helps create dynamic brain models 3Engineering control theory helps create dynamic brain models 4
... Each vial contains 200 g of ... receptor sequence (C-terminal amino acids 380-402; GLTPSAWEASSLRSSRHSGLSHF. ... an antigen for production of Cayman's EP1 ... can be used in conjunction with this ...
Anti-ZFP200 Family: Zinc Finger Peptide Sequence: CGKSFNHKTNLNKHER...
Complete cell culture media with cytokines...
Consists of 4 separate 100mM solutions (ATP,GTP,CTP and UTP pH 7.5) as sodium salts. 98% Pure by HPLC...
Biology Products: